Skip to main content
Erschienen in: Obesity Surgery 5/2016

02.09.2015 | Original Contributions

Is a Simple Food-Diverting Operation the Solution for Type 2 Diabetes Treatment? Experimental Study in a Non-Obese Rat Model

verfasst von: John Melissas, Drakos Peirasmakis, Vasileios Lamprou, John Papadakis

Erschienen in: Obesity Surgery | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The feasibility of a side-to-side jejunoileal anastomosis (SJA) to control type 2 diabetes mellitus (T2DM) was studied in non-obese diabetic Goto–Kakizaki (GK) rats.

Methods

Seventeen 14-week-old male GK rats were divided into three groups: SJA bypassing 60 % of the small bowel length, sham-operated jejunoileal bypass (Sham group), and control animals. Rats were observed for 10 weeks after surgery. Fasting blood glucose (FBG) levels and oral glucose tolerance test (OGTT) were measured before and after the procedure.

Results

Animals with SJA exhibited normalization of FBG levels from the 1st and up to the 10th postoperative week when the experiment terminated. OGTT compared with sham-operated and control groups was also significantly better at 3 and 8 weeks postoperatively.

Conclusions

A simple SJA, diverting the food and biliopancreatic secretion to the distal small bowel, was able to normalize both FBG levels and OGTT in a non-obese diabetic rat model.
Literatur
1.
Zurück zum Zitat Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13.CrossRefPubMed Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13.CrossRefPubMed
2.
Zurück zum Zitat De Sa VC, Ferraz AA, Campos JM, et al. Gastric bypass in the treatment of type 2 diabetes in patients with a BMI of 30 to 35 kg/m2. Obes Surg. 2011;21(3):283–7.CrossRefPubMed De Sa VC, Ferraz AA, Campos JM, et al. Gastric bypass in the treatment of type 2 diabetes in patients with a BMI of 30 to 35 kg/m2. Obes Surg. 2011;21(3):283–7.CrossRefPubMed
3.
Zurück zum Zitat Scopinaro N, Papadia F, Marinari G, et al. Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/m2. Obes Surg. 2007;17(2):185–92.CrossRefPubMed Scopinaro N, Papadia F, Marinari G, et al. Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/m2. Obes Surg. 2007;17(2):185–92.CrossRefPubMed
4.
Zurück zum Zitat Rubino F, Kaplan LM, Schauer PR, et al. The Diabetes Surgery Summit Consensus conference recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251(3):399–405.CrossRefPubMed Rubino F, Kaplan LM, Schauer PR, et al. The Diabetes Surgery Summit Consensus conference recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251(3):399–405.CrossRefPubMed
5.
Zurück zum Zitat Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007;3(2):195–7.CrossRefPubMed Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007;3(2):195–7.CrossRefPubMed
6.
Zurück zum Zitat De Paula AL, Stival AR, Halpern A, et al. Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. J Gastrointest Surg. 2011;15(8):1344–53.CrossRefPubMed De Paula AL, Stival AR, Halpern A, et al. Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. J Gastrointest Surg. 2011;15(8):1344–53.CrossRefPubMed
7.
Zurück zum Zitat Santoro S, Castro LC, Velhote MC, et al. Sleeve gastrectomy with transit bipartition: a potent for metabolic syndrome and obesity. Ann Surg. 2012;256(1):104–10.CrossRefPubMed Santoro S, Castro LC, Velhote MC, et al. Sleeve gastrectomy with transit bipartition: a potent for metabolic syndrome and obesity. Ann Surg. 2012;256(1):104–10.CrossRefPubMed
8.
Zurück zum Zitat Melissas J, Peppe A, Askoxilakis J, et al. Sleeve gastrectomy plus side-to-side jejunoileal anastomosis for the treatment of morbid obesity and metabolic diseases: a promising operation. Obes Surg. 2012;22(7):1104–9.CrossRefPubMed Melissas J, Peppe A, Askoxilakis J, et al. Sleeve gastrectomy plus side-to-side jejunoileal anastomosis for the treatment of morbid obesity and metabolic diseases: a promising operation. Obes Surg. 2012;22(7):1104–9.CrossRefPubMed
9.
Zurück zum Zitat Dimitriadis E, Daskalakis M, Kampa M, et al. Alterations in gut hormones after laparoscopic sleeve gastrectomy: a prospective clinical and laboratory investigational study. Ann Surg. 2013;257(4):647–54.CrossRefPubMed Dimitriadis E, Daskalakis M, Kampa M, et al. Alterations in gut hormones after laparoscopic sleeve gastrectomy: a prospective clinical and laboratory investigational study. Ann Surg. 2013;257(4):647–54.CrossRefPubMed
10.
Zurück zum Zitat Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234–41.CrossRefPubMed Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234–41.CrossRefPubMed
11.
Zurück zum Zitat De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver. 2012;6(1):10–20.CrossRefPubMedPubMedCentral De Silva A, Bloom SR. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver. 2012;6(1):10–20.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.CrossRefPubMed Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.CrossRefPubMed
13.
Zurück zum Zitat Melissas J, Daskalakis M, Koukouraki S, Dimitriadis E, et al. Sleeve gastrectomy—a “food limiting” operation. Obes Surg. 2008;18(10):1251–6.CrossRefPubMed Melissas J, Daskalakis M, Koukouraki S, Dimitriadis E, et al. Sleeve gastrectomy—a “food limiting” operation. Obes Surg. 2008;18(10):1251–6.CrossRefPubMed
14.
Zurück zum Zitat Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Ann Surg. 2013;258(6):976–82.CrossRefPubMed Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Ann Surg. 2013;258(6):976–82.CrossRefPubMed
15.
Zurück zum Zitat Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, et al. Sleeve gastrectomy as sole and definite bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20(5):535–40.CrossRefPubMed Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, et al. Sleeve gastrectomy as sole and definite bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20(5):535–40.CrossRefPubMed
16.
Zurück zum Zitat Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology type 2 diabetes. Ann Surg. 2006;244(5):741–9.CrossRefPubMedPubMedCentral Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology type 2 diabetes. Ann Surg. 2006;244(5):741–9.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis. 2008;18(8):574–9.CrossRefPubMed Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis. 2008;18(8):574–9.CrossRefPubMed
18.
Zurück zum Zitat Bikman BT, Zheng D, Pories WJ, et al. Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab. 2008;93(12):4656–63.CrossRefPubMedPubMedCentral Bikman BT, Zheng D, Pories WJ, et al. Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab. 2008;93(12):4656–63.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Chambers AP, Jessen L, Ryan KK, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology. 2011;141(3):950–8.CrossRefPubMedPubMedCentral Chambers AP, Jessen L, Ryan KK, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology. 2011;141(3):950–8.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206.CrossRefPubMed Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206.CrossRefPubMed
21.
Zurück zum Zitat Sun D, Liu S, Zhang G, et al. Type 2 diabetes control in a nonobese rat model using sleeve gastrectomy with duodenal-jejunal bypass (SGDJB). Obes Surg. 2012;22(12):1865–73.CrossRefPubMed Sun D, Liu S, Zhang G, et al. Type 2 diabetes control in a nonobese rat model using sleeve gastrectomy with duodenal-jejunal bypass (SGDJB). Obes Surg. 2012;22(12):1865–73.CrossRefPubMed
22.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMed Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMed
23.
Zurück zum Zitat Akash MS, Rehman K, Chen S. Goto–Kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Curr Diabetes Rev. 2013;9(5):387–96.CrossRefPubMed Akash MS, Rehman K, Chen S. Goto–Kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Curr Diabetes Rev. 2013;9(5):387–96.CrossRefPubMed
24.
Zurück zum Zitat Stein J, Stier C, Raab H, et al. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40(6):582–609.CrossRefPubMed Stein J, Stier C, Raab H, et al. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40(6):582–609.CrossRefPubMed
25.
Zurück zum Zitat Topart P, Becouam G, Salle A, et al. Biliopancreatic diversion requires multiple vitamin and micronutrient adjustments within 2 years of surgery. Surg Obes Relat Dis. 2014;10(5):936–41.CrossRefPubMed Topart P, Becouam G, Salle A, et al. Biliopancreatic diversion requires multiple vitamin and micronutrient adjustments within 2 years of surgery. Surg Obes Relat Dis. 2014;10(5):936–41.CrossRefPubMed
26.
Zurück zum Zitat Penney NC, Kinross JM, Newton RC, Purkayastha S. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes (Lond) 2015 Jun 17 doi: 10.1038/ijo.2015.115 Penney NC, Kinross JM, Newton RC, Purkayastha S. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes (Lond) 2015 Jun 17 doi: 10.1038/ijo.2015.115
27.
Zurück zum Zitat Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Konigsrainer A et al. Effect of surgical and dietary weight loss therapy for obesity in gut microbiota composition and nutrient absorption. Biomed Res Int 2015:806248 doi: 10.1155/2015/806248 Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Konigsrainer A et al. Effect of surgical and dietary weight loss therapy for obesity in gut microbiota composition and nutrient absorption. Biomed Res Int 2015:806248 doi: 10.​1155/​2015/​806248
28.
Zurück zum Zitat Lakhani SV, Shah HN, Alexander K, et al. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass in obese patients. Nutr Res. 2008;28(5):293–8.CrossRefPubMed Lakhani SV, Shah HN, Alexander K, et al. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass in obese patients. Nutr Res. 2008;28(5):293–8.CrossRefPubMed
29.
Zurück zum Zitat Ishida RK, Faintuch J, Paula AM, et al. Microbial flora of the stomach after gastric bypass for morbid obesity. Obes Surg. 2007;17(6):752–8.CrossRefPubMed Ishida RK, Faintuch J, Paula AM, et al. Microbial flora of the stomach after gastric bypass for morbid obesity. Obes Surg. 2007;17(6):752–8.CrossRefPubMed
Metadaten
Titel
Is a Simple Food-Diverting Operation the Solution for Type 2 Diabetes Treatment? Experimental Study in a Non-Obese Rat Model
verfasst von
John Melissas
Drakos Peirasmakis
Vasileios Lamprou
John Papadakis
Publikationsdatum
02.09.2015
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 5/2016
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-015-1871-8

Weitere Artikel der Ausgabe 5/2016

Obesity Surgery 5/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.